Wistar Scientists Identify New Therapeutic Target in Ovarian Cancer Subtype With Poor Prognosis. Ovarian clear cell carcinomas with ARID1A mutations are sensitive to inhibition of the IRE1a-XBP1 stress response pathway in preclinical models.
September 21, 2021 5:12 pmBy Wistar Institute
Newswise — PHILADELPHIA — (Sept. 21, 2021) — Mutations in the ARID1A gene are present in more than 50% of ovarian clear cell carcinomas (OCCC), for which effective treatments are lacking. Scientists at The Wistar Institute discovered … Read more